I. McCaffery

发表

Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β‐Hydroxysteroid Dehydrogenase Type 1 (11β‐HSD1) Activity After Oral Administration of AMG 221, a Selective 11β‐HSD1 Inhibitor

R. Perfetti, J. Gibbs, M. Emery, 2011, Journal of clinical pharmacology.

PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project

F. Hirsch, K. Kerr, M. Tsao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

S. Loi, M. Hellmann, L. Emens, 2017 .

Absence of functional EpoR expression in human tumor cell lines.

C. Begley, S. Elliott, A. Ellison, 2010, Blood.

Functional EpoR Pathway Utilization Is Not Detected in Primary Tumor Cells Isolated from Human Breast, Non-Small Cell Lung, Colorectal, and Ovarian Tumor Tissues

C. Begley, S. Patterson, S. Elliott, 2015, PloS one.

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.

C. Begley, A. Coxon, S. Elliott, 2010, Blood.

Lack of expression and function of erythropoietin receptors in the kidney.

C. Begley, S. Elliott, P. Kassner, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

P. Hegde, H. Koeppen, J. Bruey, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.

C. Begley, S. Elliott, I. McCaffery, 2010, Journal of immunological methods.

Determination of prednisolone in human adipose tissue incubation medium using LC-MS/MS to support the measurement of 11beta-hydroxysteroid dehydrogenase activity.

M. Emery, I. McCaffery, J. Rossi, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.

J. Nemunaitis, R. Doebele, M. Hellmann, 2017 .

Analysis of cell surface erythropoietin receptor (EpoR) expression and function in human epithelial tumor tissues.

S. Patterson, S. Elliott, I. McCaffery, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

A. Tolcher, I. Puzanov, K. Papadopoulos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translation of Protein Biomarkers for Clinical Development

J. Ferbas, S. Patterson, S. Suggs, 2008 .

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

J. Desai, G. Demetri, A. Tolcher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Novel Method for Mutation Analysis Using Genomic DNA Obtained from Immunohistochemistry-Stained Sections

L. Amler, H. Koeppen, I. McCaffery, 2015 .

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

A. Hotson, E. Piccione, Richard A. Miller, 2018, Cancer Immunology Research.

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

J. Robertson, H. Kennecke, P. Kaufman, 2013, The Lancet. Oncology.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

T. Choueiri, R. Heist, M. Sznol, 2019, Cancer discovery.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

I. Puzanov, E. Chan, J. Gilbert, 2012, Clinical Cancer Research.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, M. Sznol, 2019 .

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial

M. Shah, Y. Bang, F. Lordick, 2017, JAMA oncology.

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

R. Loberg, J. Tabernero, S. Choo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of novel elements which regulate the cell-type specificity of Dictyostelium 7E gene expression.

B. Hames, I. McCaffery, J. Seager, 2001, Differentiation; research in biological diversity.

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

C. Fuchs, S. Patterson, H. Kindler, 2013, Clinical Cancer Research.

Transcription of the Dictyostelium glycogen phosphorylase-2 gene is induced by three large promoter domains.

I. McCaffery, C. Rutherford, R. Favis, 1998, Developmental genetics.

AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.

J. Desai, G. Demetri, A. Tolcher, 2010 .

Multilamellar endosome-like compartment accumulates in the yeast vps28 vacuolar protein sorting mutant.

K. Köhrer, S. Emr, J. McCaffery, 1996, Molecular biology of the cell.

Abstract 5598: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models

A. Hotson, I. McCaffery, S. Willingham, 2017 .

Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies

A. Hotson, I. McCaffery, S. Willingham, 2016 .

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, B. Rini, 2020 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Absence of functional EpoR expression in human tumor cell lines.

S. Elliott, P. Kassner, I. McCaffery, 2010, Blood.

Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.

S. Elliott, I. McCaffery, J. Rossi, 2010, Journal of immunological methods.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers

M. Mouksassi, I. McCaffery, Jianfeng Lu, 2013, Clinical pharmacology in drug development.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, N. Tebbutt, 2014, Clinical Cancer Research.

Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab

P. Hegde, H. Koeppen, J. Bruey, 2016 .